Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
55.92
-0.32 (-0.57%)
Jun 16, 2026, 4:00 PM EDT - Market closed
Bristol-Myers Squibb Company Employees
Bristol-Myers Squibb Company had 32,500 employees as of December 31, 2025. The number of employees decreased by 1,600 or -4.69% compared to the previous year.
Employees
32,500
Change (1Y)
-1,600
Growth (1Y)
-4.69%
Revenue / Employee
$1,491,754
Profits / Employee
$223,846
Market Cap
114.19B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 32,500 | -1,600 | -4.69% |
| Dec 31, 2024 | 34,100 | 0 | - |
| Dec 31, 2023 | 34,100 | -200 | -0.58% |
| Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
| Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
| Dec 31, 2020 | 30,250 | 250 | 0.83% |
| Dec 31, 2019 | 30,000 | 6,700 | 28.76% |
| Dec 31, 2018 | 23,300 | -400 | -1.69% |
| Dec 31, 2017 | 23,700 | -1,300 | -5.20% |
| Dec 31, 2016 | 25,000 | 0 | - |
| Dec 31, 2015 | 25,000 | 0 | - |
| Dec 31, 2014 | 25,000 | -3,000 | -10.71% |
| Dec 31, 2013 | 28,000 | 0 | - |
| Dec 31, 2012 | 28,000 | 1,000 | 3.70% |
| Dec 31, 2011 | 27,000 | 0 | - |
| Dec 31, 2010 | 27,000 | -1,000 | -3.57% |
| Dec 31, 2009 | 28,000 | -7,000 | -20.00% |
| Dec 31, 2008 | 35,000 | -7,000 | -16.67% |
| Dec 31, 2007 | 42,000 | -1,000 | -2.33% |
| Dec 31, 2006 | 43,000 | 0 | - |
| Dec 31, 2005 | 43,000 | 0 | - |
| Dec 31, 2004 | 43,000 | -1,000 | -2.27% |
| Dec 31, 2003 | 44,000 | 0 | - |
| Dec 31, 2002 | 44,000 | -2,000 | -4.35% |
| Dec 31, 2001 | 46,000 | 2,000 | 4.55% |
| Dec 31, 2000 | 44,000 | -10,500 | -19.27% |
| Dec 31, 1999 | 54,500 | -200 | -0.37% |
| Dec 31, 1998 | 54,700 | 1,100 | 2.05% |
| Dec 31, 1997 | 53,600 | 2,400 | 4.69% |
| Dec 31, 1996 | 51,200 | 2,060 | 4.19% |
| Dec 31, 1995 | 49,140 | 1,440 | 3.02% |
| Dec 31, 1994 | 47,700 | -1,800 | -3.64% |
| Dec 31, 1993 | 49,500 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
BMY News
- 6 days ago - Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters
- 7 days ago - Bristol-Myers Squibb Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 8 days ago - The space race is coming for pharma: Why drug development is heading to lower Earth orbit - CNBC
- 9 days ago - Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease - Business Wire
- 13 days ago - Arcus enters clinical trial collaboration, supply agreement with Bristol Myers - TheFly
- 13 days ago - Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer - Business Wire
- 14 days ago - Bristol Myers, SystImmune announce results from analyses of iza-bren studies - TheFly
- 14 days ago - Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma - Business Wire